ea0005p149 | Endocrine Tumours and Neoplasia | BES2003
Lindsay J
, McConnell E
, Hunter S
, McCance D
, Sheridan B
, Atkinson A
From a group of 41 patients with acromegaly, the majority of whom had pituitary surgery as primary therapy, we have compared growth hormone responses to a test dose of octreotide across 8 hours with a 3 year random growth hormone in 22 patients who at the 3 year assessment were receiving at least 600mcg octreotide daily subcutaneously or 20mg LAR monthly intramuscularly and in 2 other patients who had achieved 3 year GH of <5 mU/l on smaller doses. Seven patients had a basa...